Dasatinib

• Description :

  Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of [1]. Dasatinib also induces apoptosis and autophagy.

• Product Name Alternative :

  BMS-354825

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Autophagy; Bcr-Abl; Src

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Dasatinib.html

• Concentration :

  10mM

• Purity :

  99.85

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C

• Molecular Formula :

  C22H26ClN7O2S

• Molecular Weight :

  488.02

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lombardo LJ, et al. Discovery of N- (2-chloro-6-methyl- phenyl) -2- (6- (4- (2-hydroxyethyl) - piperazin-1-yl) -2-methylpyrimidin-4- ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47 (27) :6658-61.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Bcr-Abl

• Citation 01 :

  ACS Environ Au. 2025 Aug 8.|ACS Omega. 2022 Oct 26;7 (44) :39760-39771.|ACS Pharmacol Transl Sci. 2023 May 2;6 (5) :738-747.|Acta Pharmacol Sin. 2024 Dec;45 (12) :2657-2671.|Adv Funct Mater. 27 January 2022.|Aging. 2020 Jun 25;12 (12) :11337-11348.|Artif Cells Nanomed Biotechnol. 2023 Dec;51 (1) :532-546.|Behav Brain Res. 2023 Feb 25:440:114260.|Biochem Pharmacol. 2023 Mar:209:115442.|Bioconjug Chem. 2023 Aug 16;34 (8) :1447-1458.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Pharm Bull. 2017;40 (10) :1747-1753. |Biomark Res. 2025 May 7;13 (1) :70.|Biomaterials. 2022 Oct:289:121800.|Biomed Chromatogr. 2019 Dec;33 (12) :e4674.|Biomed Pharmacother. 2023 Jun:162:114680.|Biomed Pharmacother. 2024 Feb:171:116124.|Biomolecules. 2022 Jun 11;12 (6) :819.|Biomolecules. 2025 Jun 16;15 (6) :873.|Bioorg Chem. 2025 Apr 5:160:108424.|bioRxiv. 2023 Dec 14.|bioRxiv. 2024 Jul 30:2024.07.29.605645.|bioRxiv. 2024 July 19.|bioRxiv. 2024 Oct 23:2024.10.20.619300.|bioRxiv. 2025 Aug 2:2025.07.31.667978.|bioRxiv. 2025 February 18.|bioRxiv. 2025 February 26.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Nov 14.|bioRxiv. 2025 Oct 25.|bioRxiv. 2025 Sep 30.|bioRxiv. 2025 Sep 5.|Blood Vessel Thromb Hemost. 2025 Nov 17.|Br J Cancer. 2023 Jan;128 (1) :148-159.|Br J Pharmacol. 2024 Aug 8.|Breast Cancer Res Treat. 2020 Jan;179 (2) :337-347.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cancer Cell Int. 2023 Dec 16;23 (1) :323.|Cancer Cell. 2025 Apr 14;43 (4) :740-756.e8.|Cancer Cell. 2025 Jun 20:S1535-6108 (25) 00255-7.|Cancer Med. 2025 Sep;14 (18) :e71227.|Cancers (Basel) . 2022 Mar 11;14 (6) :1451.|Cell Biochem Funct. 2020 Jul;38 (5) :642-650.|Cell Commun Signal. 2024 Feb 12;22 (1) :115.|Cell Death Dis. 2021 Dec 3;12 (12) :1126.|Cell Death Dis. 2025 Feb 3;16 (1) :64.|Cell Mol Gastroenterol Hepatol. 2022 Apr 2;14 (1) :75-99.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell Signal. 2024 Oct:122:111307.|Cell Stem Cell. 2025 Dec 4;32 (12) :1869-1885.e8.|Cell. 2021 Oct 28;184 (22) :5670-5685.e23.|Cells. 2023 Dec 14;12 (24) :2836.|Chem Biol Interact. 2022 Jan 5:351:109729.|Chem Pharm Bull (Tokyo) . 2017 Aug 1;65 (8) :768-775.|Clin Exp Immunol. 2025 May 8:uxaf029.|Clin Exp Ophthalmol. 2025 Jul 14.|Clin Sci. 2021 Jul 30;135 (14) :1751-1765.|Discov Oncol. 2024 Nov 19;15 (1) :678.|Diseases. 2023 Oct 23;11 (4) :147.|Drug Des Devel Ther. 2024 Dec 5:18:5641-5654.|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.|Eur J Pharmacol. 2021 Apr 15:897:173944.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Eye Res. 2022 Oct:223:109207.|FASEB J. 2024 Jan;38 (1) :e23355.|FEBS J. 2024 Dec;291 (24) :5435-5454.|Front Cell Dev Biol. 2021 Mar 16:9:618045.|Front Microbiol. 2019 Aug 7:10:1816.|Front Pharmacol. 2021 Mar 8;12:644342.|Gerontology. 2022;68 (8) :920-934.|Harvard Medical School LINCS LIBRARY|Hear Res. 2024 Dec 4:455:109165.|Hum Exp Toxicol. 2023 Jan-Dec:42:9603271231188492.|Immunity. 2024 Mar 12;57 (3) :513-527.e6.|Int J Biol Macromol. 2025 Jun 4;318 (Pt 1) :144963.|Int J Biol Sci. 2025 Jan 6;21 (3) :940-954.|Int J Med Sci. 2025 Jan 1;22 (1) :110-120.|Int J Rheum Dis. 2023 Apr;26 (4) :718-726.|iScience. 2023 Jul 27;26 (8) :107477.|J Am Chem Soc. 2025 Aug 6;147 (31) :27876-27891.|J Anim Sci Biotechnol. 2021 May 10;12 (1) :63.|J Cancer Res Clin Oncol. 2023 Feb;149 (2) :669-682.|J Chem Inf Model. 2024 Jun 24;64 (12) :4835-4849.|J Clin Invest. 2019 Mar 1;129 (3) :972-987.|J Clin Invest. 2023 Apr 3;133 (7) :e162324.|J Hematol Oncol. 2022 Apr 29;15 (1) :46.|J Hematol Oncol. 2024 Dec 18;17 (1) :122.|J Immunol Res. 2022 Apr 28;2022:6324326.|J Immunother Cancer. 2020 Mar;8 (1) :e000111. |J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Med Chem. 2021 Oct 14;64 (19) :14344-14357.|J Med Chem. 2024 Nov 28;67 (22) :20571-20579.|J Nat Med. 2025 May;79 (3) :621-638.|J Pharm Anal. 2021 Dec;11 (6) :799-807.|J Pineal Res. 2019 Sep;67 (2) :e12588. |J Prosthodont Res. 2025 Feb 11.|J Toxicol Sci. 2024;49 (8) :337-348.|J Transl Med. 2022 Jun 21;20 (1) :278.|J Virol. 2024 Sep 17:e0112924.|JCI Insight. 2025 Jan 23;10 (2) :e180248.|Kawasaki Medical Journal. 43 (2) : 63-78, 2017.|Leukemia. 2012 Oct;26 (10) :2233-44.|Leukemia. 2020 Jun;34 (6) :1524-1539. |Matrix Biol. 2024 Mar:127:48-56.|Med Oncol. 2022 Dec 16;40 (1) :49.|Mol Cancer Ther. 2025 Jul 2.|Mol Cell. 2025 Sep 18;85 (18) :3425-3442.e10.|Mol Hum Reprod. 2025 Jul 3;31 (3) :gaaf032.|Mol Ther. 2023 Jun 7;31 (6) :1846-1856.|Molecules. 2018 Mar 23;23 (4) . pii: E736.|Nat Aging. 2024 Apr;4 (4) :527-545.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Cell Biol. 2023 Mar;25 (3) :493-507.|Nat Commun. 2020 Apr 14;11 (1) :1790.|Nat Commun. 2020 Apr 20;11 (1) :1913. |Nature. 2025 Nov 26.|NPJ Precis Oncol. 2025 Aug 16;9 (1) :289.|Oncogenesis. 2022 Apr 11;11 (1) :15.|Oncotarget. 2016 Aug 30;7 (35) :56241-56252. |Patent. US10174018B2.|Patent. US20180099959A1.|Patent. US20180099960A1.|Patent. US20180099961A1.|Patent. US20180263995A1.|Patent. US20230226111A1.|Patent. US20240238271A1.|Patent. US20240319170A1|Patent. US20240325538A1.|PLoS One. 2013;8 (2) :e56473.|PLoS One. 2018 Jun 14;13 (6) :e0199208.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Purdue University. Department of Chemistry.|Res Sq. 2025 Apr 14.|Res Sq. 2025 May 16:rs.3.rs-6590535.|Res Sq. 2025 Sep 23.|Research Square Print. 2025 May 28.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Sci Adv. 2025 Nov 28;11 (48) :eadz2345.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|SSRN. 2024 Apr 1.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Target Oncol. 2020 Oct;15 (5) :659-671.|Technical University of Munich. 24.01.2018.|University of Düsseldorf. 2024.|University of New York. 2025.|University of Otago. 2025 Oct 7.|bioRxiv. 2025 Jun 27.|Front Pharmacol. 2023 Aug 29:14:1250383.|J Hematol Oncol. 2018 Aug 29;11 (1) :109. |PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |University of Osaka. 2025.|Int J Pharm Res Allied Sci. 2023 Mar;13 (1) :139-148.

• CAS Number :

  [302962-49-8]